Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Subject: search.filters.subject.Biomarker

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Current adjuvant treatment modalities for gastric cancer: From history to the future
    (BAISHIDENG PUBLISHING GROUP INC, 2016-01-01) Kilic, Leyla; Ordu, Cetin; Yildiz, Ibrahim; Sen, Fatma; Keskin, Serkan; Ciftci, Rumeysa; Pilanci, Kezban Nur
    The discrepancy between the surgical technique and the type of adjuvant chemotherapy used in clinical trials and patient outcomes in terms of overall survival rates has led to the generation of different adjuvant treatment protocols in distinct parts of the world. The adjuvant treatment recommendation is generally chemoradiotherapy in the United States, perioperative chemotherapy in the United Kingdom and parts of Europe, and chemotherapy in Asia. These options mainly rely on the United States Intergroup-0116, United Kingdom British Medical Research Council Adjuvant Gastric Infusional Chemotherapy, and the Asian Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer and Capeci-tabine and Oxaliplatin Adjuvant Study in Stomach Cancer trials. However, the benefits were evident for only certain patients, which were not very homogeneous regarding the type of surgery, chemotherapy regimens, and stage of disease. Whether the dissimilarities in survival are attributable to surgical technique or intrinsic biological differences is a subject of debate. Regardless of the extent of surgery, multimodal therapy may offer modest survival advantage at least for diseases with lymph node involvement. Moreover, in the era of individualized treatment for most of the other cancer types, identification of special subgroups comprising those who will derive more or no benefit from adjuvant therapy merits further investigation. The aim of this review is to reveal the historical evolution and future reflections of adjuvant treatment modalities for resected gastric cancer patients.
  • No Thumbnail Available
    Item
    Platelet to Lymphocyte Ratio in Neonates: A Predictor of Early onset Neonatal Sepsis
    (MATTIOLI 1885, 2019-01-01) Arcagok, Baran Cengiz; Karabulut, Birol
    Background: Neonatal sepsis (NS) is a common systemic disease that causes morbidity and mortality in newborns. But there is no ideal biomarker that can be used in the early diagnosis of NS. In recent studies, platelet to lymphocyte ratio (PLR) has been reported to play a critical role in the inflammatory process. In this study, we aimed to contribute to the research about whether or not PLR can be used as an early predictor of the diagnosis of NS. Methods: This retrospective cohort study was conducted among the newborns born in Izmir Buca Maternity and Pediatric Hospital between March 2015-February 2016. During these twelve months, 611 neonates with Early-Onset Sepsis (EOS) were admitted to our neonatal intensive care unit. One hundred and forty-nine neonates with suspected EOS, 67 neonates with proven EOS and 92 healthy neonates were enrolled in the study. Results: Platelet to lymphocyte ratio (PLR) values of the three groups were calculated 56.5 +/- 17.8 vs. 62.4 +/- 14.9 vs. 15.3 +/- 2.1, respectively. PLR values of suspected or proven EOS group were significantly higher than the control group. PLR has AUC 0.89 to 0.93, the cutoff value of 39.5 to 57.7, the sensitivity of 88.9\% to 91.3\% and specificity of 94.7\% to 97.6\%, the positive predictive value of 94.3\% to 97.4\%, and negative predictive value of 88.6\% to 91.8\% in suspected and proven sepsis diagnosis. Conclusions: Our results suggest that PLR can be used as a parameter in the prediction of neonatal sepsis.
  • Thumbnail Image
    Item
    Cofilin-1 as a potential biomarker to evaluate acute kidney injury
    (WALTER DE GRUYTER GMBH, 2019-01-01) Coskun, Abdurrahman; Ucal, Yasemin; Berber, Ibrahim; Cakir, Ulkem; Serteser, Mustafa; Moldur, Derya Emel; Derelioglu, Ecenur Izzete; Yozgatli, Tahir Koray; Ozpinar, Aysel; Unsal, Ibrahim
    Acute kidney injury (AKI) is a worldwide health problem and defined by rapid loss of excretory function of the kidney with the accumulation of metabolic end products. For effective treatment and prevent complications the early diagnosis of AKI is crucial. The current analytes used to diagnose AKI are not adequately sensitive and specific and therefore clinicians need new biomarkers. One of the new promising biomarker candidates of renal injury is cofilin-1. Previously, in our laboratory we isolated cofilin-1 in kidney preservation solution prior to transplantation and attempted to measure serum cofilin-1 in renal transplanted patients. However, cofilin-1 was not accurately measured in serum samples due to the methodological issues. In this mini-review, we summarized the current knowledge and concepts both in the literature and our experiences with cofilin-1 as a potential biomarker for the diagnosis and management of AKI.